[Year:2017] [Month:April-June] [Volume:1] [Number:2] [Pages:9] [Pages No:99 - 107]
Introduction: Anemia is a condition in which the number of red blood cells (RBCs) or their oxygen-carrying capacity is insufficient to meet physiologic needs of the body and is characterized by a constellation of symptoms. Ayurveda compares the symptoms of anemia with that of the disease Pandu. Punarnavadi Mandura, Dadimadi Ghrta, Navayasa Churna, and Dhatri Lauha are few among the multitudes of medicines that are currently prevalent in use for the management of Pandu. However, the safety of these drugs were not evaluated until now through clinical drug trials.
Objective: Critical analysis and presentation of clinical safety and efficacy outcomes of classical Ayurvedic formulations, viz., Dhatri Lauha, Navayasa Churna, Punarnavadi Mandura, and Dadimadi Ghrta in iron deficiency anemia (IDA).
Materials and methods: A retrospective analysis of data collected from three different clinical studies that had been completed in peripheral institutes of Central Council for Research in Ayurvedic Sciences (CCRAS) were critically evaluated to assay the safety profile of four drugs, namely Dhatri Lauha, Navayasa Churna, Punarnavadi Mandura, and Dadimadi Ghrta in patients of IDA. Safety assessments were done through analyzing liver function test (LFT) and renal function test before and after the trial period. Paired sample t-test was used to compare the mean changes from baseline to the end of the trial period. A p-value of <0.05 was considered significant. Drug compliance and adverse drug reaction (ADR)/adverse events (AE), if any, were noted.
Conclusion: The findings in the three different clinical studies clearly reveal that Punarnavadi Mandura, Navayasa Churna, Dhatri Lauha, and Dadimadi Ghrta are clinically safe, effective, and tolerable.